Position in EPRX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,058,585
+$166,224 QoQ
Shares Held
311,435
+19.2% QoQ
Ownership
0.471%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#25
of 68 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ROYAL BANK OF CANADA holds $2,116,200,383 across 427 Biotechnology names. EPRX ranks #46 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
6,182,479 | $490,208,754 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
980,259 | $486,924,048 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
875,859 | $263,659,830 | |
| 4 | INCY |
Incyte Corp
|
1,132,050 | $128,329,182 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
174,515 | $108,817,078 | |
| 6 | MRNA |
Moderna, Inc.
|
944,457 | $66,140,319 | |
| 7 | INSM |
INSMED Inc
|
416,487 | $44,405,840 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
545,761 | $42,716,712 |
All Filings in EPRX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,058,585 | 311,435 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $1,892,361 | 261,376 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,481,891 | 196,277 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $2,529,943 | 428,804 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $2,468,643 | 428,584 | Shares | Defined | 2025-11-21 | |
| 2025-03-31 | $1,124,475 | 342,828 | Shares | Defined | 2025-11-21 | |
| 2024-12-31 | $897,569 | 283,145 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $713,484 | 271,287 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $685,619 | 265,744 | Shares | Defined | 2024-11-06 | |
| No filing history on record for this holder in this stock. | ||||||